Targeted Amatoxin Conjugate for Treatment of Solid Tumors
Summary
Heidelberg Pharma Research GmbH has published a US patent application (US20260097093A1) for a targeted amatoxin-linker conjugate designed to treat solid tumors. The application discloses an amatoxin-linker construct where R1 and R2 are each OH, R3 is NH2 or a linker, R4 is H or a linker, and R5 is absent or O, with the conjugate useful in manufacturing binding moiety-toxin therapeutics. Filing date was October 6, 2025.
What changed
Heidelberg Pharma Research GmbH published a US patent application covering a targeted amatoxin-linker construct and its use in manufacturing binding moiety-toxin conjugates for treating solid tumors. The application discloses compounds where R1 and R2 are each OH, R3 is NH2 or a reactive linker group Y, R4 is H or a reactive linker group Y, with the constraint that R3 and R4 cannot be identical. The filing is classified under CPC codes A61K 38/12, A61K 47/65, A61K 47/6831, A61K 47/6871, and A61P 35/00.
Pharmaceutical and biotech companies developing antibody-drug conjugates or toxin-based oncology therapeutics should monitor this application's prosecution for potential licensing opportunities, competitive landscape insights, or freedom-to-operate concerns in the solid tumor treatment space.
What to do next
- Monitor application prosecution status for grant or rejection
- Review claims for freedom-to-operate implications in solid tumor therapeutics
- Assess potential licensing or partnership opportunities with Heidelberg Pharma
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TARGETED AMATOXIN CONJUGATE FOR THE TREATMENT OF SOLID TUMORS
Application US20260097093A1 Kind: A1 Apr 09, 2026
Assignee
Heidelberg Pharma Research GmbH
Inventors
Christoph Müller, Werner Simon, Christian Lutz, Susanne Werner-Simon, Torsten Hechler, Michael Kulke, Andreas Pahl
Abstract
An amatoxin-linker construct contains an amatoxin according to formula (I) wherein R1 and R2 are each —OH, R3 is NH2, or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety, R4 is H or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety, R5 is absent or ═O, and wherein R3 and R4 cannot be the same. The amatoxin-linker construct is used in the manufacture of a binding moiety-toxin conjugate for the treatment of a solid tumor, and a respective binding moiety-toxin conjugate can be used for the treatment of a solid tumor.
CPC Classifications
A61K 38/12 A61K 47/65 A61K 47/6831 A61K 47/6871 A61P 35/00
Filing Date
2025-10-06
Application No.
19350762
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.